Armata Pharmaceuticals, Inc. financial data

Symbol
ARMP on NYSE
Location
Los Angeles, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 12% % -62%
Debt-to-equity -229% % 30%
Return On Equity 70% % -21%
Return On Assets -55% % -40%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36,329,842 shares 0.41%
Common Stock, Shares, Outstanding 3,622,842 shares -90%
Entity Public Float $30,300,000 USD 142%
Common Stock, Value, Issued $362,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 36,226,285 shares 0.13%
Weighted Average Number of Shares Outstanding, Diluted 36,226,285 shares 0.13%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense $12,306,000 USD -5.6%
Operating Income (Loss) $33,349,000 USD 20%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $46,901,000 USD -13%
Earnings Per Share, Basic -1 USD/shares -14%
Earnings Per Share, Diluted -1 USD/shares 24%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $14,756,000 USD -14%
Other Assets, Current $759,000 USD -66%
Assets, Current $16,930,000 USD -24%
Property, Plant and Equipment, Net $12,560,000 USD -7.8%
Operating Lease, Right-of-Use Asset $39,917,000 USD -5.5%
Intangible Assets, Net (Excluding Goodwill) $10,256,000 USD 0%
Goodwill $3,490,000 USD 0%
Other Assets, Noncurrent $973,000 USD 29%
Assets $89,516,000 USD -8.9%
Accounts Payable, Current $1,280,000 USD -29%
Liabilities, Current $139,950,000 USD 18%
Deferred Income Tax Liabilities, Net $3,077,000 USD 0%
Operating Lease, Liability, Noncurrent $26,837,000 USD -3.9%
Liabilities $185,104,000 USD 24%
Retained Earnings (Accumulated Deficit) $377,236,000 USD -14%
Stockholders' Equity Attributable to Parent $95,588,000 USD -88%
Liabilities and Equity $89,516,000 USD -8.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $7,580,000 USD 28%
Net Cash Provided by (Used in) Financing Activities $9,986,000 USD -71%
Net Cash Provided by (Used in) Investing Activities $99,000 USD 60%
Common Stock, Shares Authorized 217,000,000 shares 0%
Common Stock, Shares, Issued 36,229,842 shares 0.13%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $2,307,000 USD -90%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $20,146,000 USD -11%
Deferred Tax Assets, Valuation Allowance $84,217,000 USD 12%
Deferred Tax Assets, Gross $97,112,000 USD 12%
Operating Lease, Liability $31,362,000 USD -4.7%
Depreciation $1,500,000 USD 15%
Payments to Acquire Property, Plant, and Equipment $99,000 USD -60%
Lessee, Operating Lease, Liability, to be Paid $61,002,000 USD -7.7%
Property, Plant and Equipment, Gross $26,819,000 USD 1.7%
Operating Lease, Liability, Current $4,525,000 USD -9.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two $5,452,000 USD 3%
Lessee, Operating Lease, Liability, to be Paid, Year One $5,293,000 USD 3%
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $29,640,000 USD -11%
Lessee, Operating Lease, Liability, to be Paid, Year Three $5,616,000 USD 3%
Deferred Tax Assets, Operating Loss Carryforwards $53,618,000 USD 15%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $5,784,000 USD 3%
Operating Lease, Payments $1,671,000 USD -50%
Additional Paid in Capital $281,286,000 USD 0.82%
Depreciation, Depletion and Amortization $377,000 USD 19%
Share-based Payment Arrangement, Expense $2,332,000 USD -15%
Interest Expense $2,718,000 USD